Welcome to LookChem.com Sign In|Join Free
  • or
2-Propanol, 1-(2-amino-3-nitrophenoxy)-3-[bis(phenylmethyl)amino]-, (2S)- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

189119-13-9

Post Buying Request

189119-13-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

189119-13-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 189119-13-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,9,1,1 and 9 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 189119-13:
(8*1)+(7*8)+(6*9)+(5*1)+(4*1)+(3*9)+(2*1)+(1*3)=159
159 % 10 = 9
So 189119-13-9 is a valid CAS Registry Number.

189119-13-9Relevant academic research and scientific papers

Potent benzimidazolone based human β3-adrenergic receptor agonists

Finley, Don R.,Bell, Michael G.,Borel, Anthony G.,Bloomquist, William E.,Cohen, Marlene L.,Heiman, Mark. L.,Kriauciunas, Aidas,Matthews, Donald P.,Miles, Tania,Neel, David A.,Rito, Christopher J.,Sall, Daniel J.,Shuker, Anthony J.,Stephens, Thomas W.,Tinsley, Frank C.,Winter, Mark A.,Jesudason, Cynthia D.

, p. 5691 - 5694 (2007/10/03)

The synthesis and biological evaluation of a series of benzimidazolone β3 adrenergic receptor agonists are described. A trend toward the reduction of rat atrial tachycardia upon increasing steric bulk at the 3-position of the benzimidazolone mo

SELECTIVE BETA 3 ADRENERGIC AGONISTS

-

, (2008/06/13)

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: STR1

Selective beta3 adrenergic agonists

-

, (2008/06/13)

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 189119-13-9